prof. dr. Piet Ost

Journal Article
A1
open access

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

P A Sutera, A C Shetty, A Hakansson, Karlien Van der Eecken (UGent) , Y Song, Y Liu, J Chang, Valerie Fonteyne (UGent) , A A Mendes, Nicolaas Lumen (UGent) , et al.

(2023) ANNALS OF ONCOLOGY. 34(7). p.605-614

Add to list

Journal Article
A1
open access

Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Yang Song, Kim Van der Eecken (UGent) , Amol C Shetty, Keara English, Theresa Hodges, Jinhee Chang, Valerie Fonteyne (UGent) , Zaker Rana, Lei Ren, et al.

(2023) EUROPEAN UROLOGY.

Add to list

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial

Piet Ost (UGent) , Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga, Wouter Everaerts, Mohamed Shelan, Antonio Conde-Moreno, et al.

(2023) EUROPEAN UROLOGY ONCOLOGY.

Add to list

WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Matthew P. Deek, Kim Van der Eecken (UGent) , Amol C. Shetty, Jin Hee Chang, Theresa Hodges, Yang Song, Sofie Verbeke (UGent) , Jo Van Dorpe (UGent) , Valerie Fonteyne (UGent) , et al.

(2023) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 115(5). p.1095-1101

Add to list

Journal Article
A1
open access

Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer

Marija Pizurica (UGent) , Maarten Larmuseau (UGent) , Kim Van der Eecken (UGent) , Louise de Schaetzen van Brienen (UGent) , Francisco Carrillo-Perez, Simon Isphording (UGent) , Nicolaas Lumen (UGent) , Jo Van Dorpe (UGent) , Piet Ost (UGent) , Sofie Verbeke (UGent) , et al.

(2023) CANCER RESEARCH. 83(17). p.2970-2984

Add to list

Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial

Mathieu Spaas (UGent) , Nora Sundahl, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Daan De Maeseneer (UGent) , Fréderic Duprez (UGent) , Yolande Lievens (UGent) , Veerle Surmont (UGent) , Lieve Brochez (UGent) , Dries Reynders (UGent) , et al.

(2023) JAMA ONCOLOGY. 9(9). p.1205-1213

Add to list

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Stephanie G C Kroeze, Matea Pavic, Karin Stellamans, Yolande Lievens (UGent) , Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, et al.

(2023) LANCET ONCOLOGY. 24(3). p.e121-e132

Add to list

Journal Article
A1
open access

Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy

Willeke Danckaert (UGent) , Piet Ost (UGent) and Carlos De Wagter (UGent)

(2023) JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS. 24(8).

Add to list

Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study

Renée Bultijnck (UGent) , Elke Rammant (UGent) , Anneleen Raes (UGent) , Nathalie Vandecasteele (UGent) , Karel Decaestecker (UGent) , Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Piet Ost (UGent) and Benedicte Deforche (UGent)

(2023) SEMINARS IN ONCOLOGY NURSING. 39(3).

Add to list

Journal Article
A1
open access

Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

Valerie Fonteyne (UGent) , Charles Van Praet (UGent) , Piet Ost (UGent) , Siska Van Bruwaene, Nick Liefhooghe, Charlien Berghen, Gert De Meerleer, Ben Vanneste (UGent) , Caroline Verbaeys, Sofie Verbeke, et al.

(2023) EUROPEAN UROLOGY FOCUS. 9(2). p.317-324

Academic Bibliography

prof. dr. Piet Ost

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial

WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer

Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer

Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy

Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study

Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

Contents

Support

Contact